To evaluate the susceptibility of rasH2 mice to N-bis(2-hydroxypropyl)nitrosamine (DHPN), a potent carcinogen targeting the lung, liver, thyroid, and kidney, male, 6-week old, rasH2 mice and wild-type Iittermates (non-Tg mice) were given DHPN in drinking water at 0, 20 or 200 ppm, and 0 or 200 ppm, respectively, for 26 weeks. The experiment using rasH2 mice given 200 ppm DHPN and non-Tg mice given 200 and 0 ppm DHPN was completed at 20 weeks, since mortality in these groups was remarkably increased due to hemangiosarcomas of the liver. Histologically, tumors developed in the lung and liver in both rasH2 and non-Tg mice treated with DHPN. In addition, proliferative lesions were observed in the forestomach, urethra, and excretory duct of salivary glands in rasH2 mice given 200 ppm DHPN. RT-PCR analysis showed no marked difference in expression of mRNAs for the transgene and the endogenous mouse ras gene between the whole lung tissue containing a neoplasm and normal lung tissue. Our results suggest that rasH2 mice are highly susceptible to DHPN, the target organs including the forestomach, salivary gland and urethra, which have not been found to develop tumors in previous long-term carcinogenicity studies of DHPN in rats and mice.
BaiF., NakanishiY., TakayamaY., PeiX. H., TokiwaH., and HaraN. (1998). Ki-ras mutation and cell proliferation of lung lesions induced by 1-nitropyrene in A/J mice. Mol Carcinog22, 258–64.
2.
DoiS. T., KimuraM., and KatsukiM. (1994). Site-specific mutation of the human c-Ha-ras transgene induced by dimethylbenzanthracene causes tissue-specific tumors in mice. Jpn J Cancer Res84, 801–07.
3.
EisenbrandG., BlankartM., SommerH., and WeberB. (1991). N-nitrosoalkanolamines in cosmeticsIARC Sci Publ105, 238–14.
4.
HiasaY., KitahoriY., KitamuraM., NishiokaH., YaneK., FukumotoM., OhshimaM., NakaokaS., and NishiiS. (1991). Relationships between serum thyroid stimulating hormone levels and development of thyroid tumors in rats treated with N-bis-(2-hydroxypropyl)nitrosamine. Carcinogenesis12, 873–7.
5.
HiasaY., OhshimaM., KitahoriY, YuasaT., FujitaT., and IwataC. (1982). Promoting effects of 3-amino-l, 2, 4-triazole on the development of thyroid tumors in rats treated with N-bis(2-hydroxypropyl)nitrosamine. Carcinogenesis3, 381–4.
6.
IssenbergP., ConradE. E., NielsenJ. W., KleinD. A., and MillerS. E. (1984). Determination of iV-nitrosobis(2-hydroxypropyl)amine in environmental samples. IARC Sci Publ57, 43–50.
7.
KawanoR., NishisakaT., TakeshimaY, YoneharaS., and InaiK. (1995). Role of point mutation of the K-ras gene in tumorigenesis of B6C3F1 mouse lung lesions induced by urethane. Jpn J Cancer Res86, 802–10.
8.
KitahoriY., HiasaY, KonishiN., EnokiN., ShimoyamaT., and MiyashiroA. (1984). Effect of propylthiouracil on the thyroid tumorigenesis induced by N-bis(2-hydroxypropyl) nitrosamine in rats. Carcinogenesis5, 657–60.
9.
KitadaH., TsutsumiM., TsujiuchiT., TakahamaM., FukudaT., NaritaN., and KonishiY (1996). Frequent mutation of Ki-ras gene but no mutation of Ha-ras and p53 in lung lesions induced by N-nitrosobis(2-hydroxypropyl)amine in rats. Mol Carcinog15, 276–83.
10.
KokkinakisD. M. (1992). Alkylation of rodent tissue DNA induced by N-nitrosobis(2-hydroxypropyl)amine. Carcinogenesis13, 759–65.
11.
KokkinakisD. M., ScarpelliD. G., SubbaraoV., and HollenbergP. F. (1987). Species differences in the metabolism of N-nitroso(2-hydroxypropyl)(2-oxopropyl)amine. Carcinogenesis8, 295–303.
12.
KonishiY., IkedaT., YoshimuraH., KawabataA., and MikamiR. (1979). Carcinogenic effect of N-bis(2-hydroxypropyl)nitrosamine by a single administration in rats. Cancer Lett6, 115–9.
13.
KonishiY., KondoH., IkedaT., KawabataA., ShojiY., and DendaA. (1978a). Effect of dose on the carcinogenic activity of orally administered N-bis(2-hydroxypropyl)nitrosamine in rats. Gann69, 573–7.
14.
KonishiY., KondoH., InuiS., DendaA., IkedaT., and KojimaK. (1978b). Organotropic effect of N-bis (2-hydroxypropyl)nitrosamine: production of lung and liver tumors by its oral administration in mice. Gann69, 77–84.
15.
MaruyamaC., TomisawaM., WakanaS., YamazakiH., KijimaH., SuemizuH., OhnishiY, UranoK., HiokiK., UsuiT., NakayamaM., TsuchidaT., MitsumoriK., NomuraX., TamaokiN., and UeyamaY. (2001). Over-expression of human H-ras transgene is responsible for tumors induced by chemical carcinogens in mice. Oncol Rep8, 233–7.
16.
MitsumoriK., KoizumiH., NomuraT., and YamamotoS. (1998). Pathological features of spontaneous and induced tumors in transgenic mice carrying a human prototype c-Ha-ras gene used for six-month carcinogenicity studies. Toxicol Pathol26, 520–31.
17.
MitsumoriK., WakanaS., YamamotoS., KodamaY, YasuharaK., NomuraT., HayashiY, and MaronpotR. R. (1997). Susceptibility of transgenic mice carrying human prototype c-Ha-ras gene in a short-term carcinogenicity study of vinyl carbamate and ras gene analyses of the induced tumors. Mole Carcinog20, 298–307.
18.
MoriY, TakahashiH., YamazakiH., ToyoshiK., MakinoT., YokoseY, and KonishiY. (1984). Distribution, metabolism and excretion of N-nitrosobis(2-hydroxypropyl)amine in Wistar rats. Carcinogenesis5, 1443–7.
19.
MoriI., YasuharaK., HayashiS., NonoyamaT., NomuraT., and MitsumoriK. (2000). Carcinogen dose-dependent variation in the transgene mutation spectrum in urethane-induced lung tumors in transgenic mice carrying the human prototypr c-Ha-ras gene. Cancer Lett153, 199–209.
20.
MortonD., AldenC. L., RothA. J., and UsuiT. (2002). The Tg rasH2 mouse in cancer hazard identification. Toxicol Pathol30, 139–46.
21.
OgawaK., ImaidaK., MasuiT., KawabeM., HasegawaR., KatoK., ItoN., and ShiraiT. (1996). Chemically induced lung and forestomach neoplasias in transgenic mice carry mutant form of the human c-Ha-ras transgene. Carcinogenesis17, 341–5.
22.
PourP., MohrU., CardesaA., AlthoffJ., and KrugerF. W. (1975). Pancreatic neoplasms in an animal model: morphological, biological, and comparative studies. Cancer36, 379–89.
23.
SaitoA., KimuraM., TakahashiR., YokoyamaM., NomuraT., IzawaM., SekiyaT., NishimuraS., and KatsukiM. (1990). Most tumors in transgenic mice with human c-Ha-ras gene contained somatically activated transgene. Oncogene5, 1195–200.
24.
ShiraiT., KurataY, FukushimaS., and ItoN. (1984). Dose-related induction of lung, thyroid and kidney tumors by N -bis(2-hydroxypropyl)nitrosamine given orally to F344 rats. Gann75, 502–7.
25.
SuemizuH., MugurumaK., MaruyamaC., TomisamaM.KimuraM., HiokiK., ShimozawaN., OhnishiY, TamaokiN., and NomuraT. (2002). Transgene stability and features of rasH2 mice as an animal model for short-term carcinogenicity testing. Mol Carcinogen34, 1–9.
26.
TakegawaK., MitsumoriK., OnoderaH., ShimoT., KitauraK., YasuharaK., and HiroseM. (2000). Studies on the carcinogenicity of potassium iodide in F344 rats. Food Chem Toxicol38, 773–81.
27.
TamaokiN. (2001). The rasH2 transgenic mouse: nature of the model and mechanistic studies on tumorigenesis. Toxicol Pathol29(suppl), 81–9.
28.
TomisawaM., SuemizuH., OhnishiY, MaruyamaC, UranoK., UsuiT., YasuharaK., TamaokiN., and MitsumoriK. (2003). Mutation analysis of vinyl carbamate or urethane induced lung tumors in rasH2 transgenic mice. Toxicol Lett142, 111–7.
29.
ToriiM., ItohF., YabuuchiK., OhnoK., KominamiG., HiranoK., TasakiT., and NaraH. (2001). Twenty-six-week carcinogenicity study of sulfamethoxazole in CB6Fl-Tg-rasH2 mice. J Toxicol Sci26, 61–73.
30.
TsuchiyaT., KobayashiK., SakairiT., GotoK., OkadaM., SanoF., SugimotoJ., MorohashiT., UsuiT., and MutaiM. (2002). Skeletal myopathy in transgenic mice carrying human prototype c-Ha-ras gene. Toxicol Pathol30, 501–6.
31.
TsutsumiM., MasutaniM., NozakiT., KusuokaO., TsujiuchiT., NakagamaH., SuzukiH., KonishiY, and SugimuraT. (2001). Increased susceptibility of poly(ADP-ribose) polymerase-I knockout mice to nitrosamine carcinogenicity. Carcinogenesis22, 1–3.
32.
UsuiT., MutaiM., HisadaS., TakaokaM., SoperK. A., McCuIloughB., and AldenC. (2001). CB6Fl-rasH2 mouse: overview of available data. Toxicol Pathol29 (suppl), 90–108.
33.
YamamotoS., HayashiY, MitsumoriK., and NomuraT. (1997). Rapid carcinogenicity testing system with transgenic mice harboring human prototype c-HRAS gene. Lab Anim Sci47, 121–6.
34.
YamamotoS., MitsumoriK., KodamaY., MatsunumaN., ManabeS., OkamiyaH., SuzukiH., FukudaT., SakamakiY., SunagaM., NomuraG., HiokiK., WakanaS., NomuraT, and HayashiY. (1996). Rapid induction of more malignant tumors by various genotoxic carcinogens in transgenic mice harboring a human prototype c-Ha-ras gene than in control non-transgenic mice. Carcinogenesis17, 2455–61.
